{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:30:52Z","timestamp":1794324652516,"version":"4.9.0"},"reference-count":0,"publisher":"ScopeMed","issue":"12","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":380,"URL":"https:\/\/www.openveterinaryjournal.com\/?sec=licenseinfo"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Open Vet J"],"published-print":{"date-parts":[[2024]]},"abstract":"<jats:p>Background: \nMethicillin resistance Staphylococcus aureus (MRSA) strains become a major challenge to the public health and health provider due to their wide spread and resistance to wide spectrum of antibacterial agents. \n\nAim: \nThis study aimed to characterize recombinant lysostaphin produced by Escherichia coli BL21(DE3) and to investigate the biosynthesis of silver nanoparticles (SNPs) by Candida albicans (C. albicans) against MRSA. \n\nMethods: \nSamples were collected from vaginal samples. The methods included efficient cloning, expression, and purification of recombinant lysostaphin, a potent antibacterial enzyme targeting Staphylococcus aureus (S. aureus), and achieved with advanced molecular techniques in E. coli BL21(DE3). The SNPs were synthesized using a biogenic approach with C. albicans, demonstrating stable and efficient silver ion reduction, as confirmed by UV-visible spectroscopy, Scanning Electron Microscope (SEM) and Fourier-transform infrared spectroscopy (FTIR) analyses. \n\nResults: \nThe antibacterial assays against MRSA strains of S. aureus showed significant inhibition by both lysostaphin and SNPs. The combination of biosynthesized SNPs\/PEG with lysostaphin exerted significant activity against tested bacteria, resulted in zone of growth inhibition 20.33 \u00b1 0.88 mm. \n\nConclusion: \nThese findings suggest a promising synergistic antibacterial strategy, offering hope in the fight against MRSA. The study findings reveal that the lysostaphin and SNPs could be effective in the treatment of MRSA-related infections, especially when used in a combination.<\/jats:p>","DOI":"10.5455\/ovj.2024.v14.i12.39","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T18:39:49Z","timestamp":1736966389000},"page":"3569","source":"Crossref","is-referenced-by-count":0,"title":["&lt;b&gt;Anti-MRSA effects of synergism of recombinant lysostaphin with biosynthesized silver nanoparticles&lt;\/b&gt;"],"prefix":"10.5455","volume":"14","author":[{"given":"Zeena","family":"Saleh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balsam","family":"Mizher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3407","container-title":["Open Veterinary Journal"],"original-title":[],"link":[{"URL":"https:\/\/www.ejmanager.com\/mnstemps\/100\/100-1728682077.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:16:45Z","timestamp":1791483405000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ejmanager.com\/mnstemps\/100\/100-1728682077.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":0,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.5455\/ovj.2024.v14.i12.39","relation":{},"ISSN":["2226-4485"],"issn-type":[{"value":"2226-4485","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}